Product Introduction
Bioactivity


英文名: Wnt-C59

描述: Wnt-C59 (C59) 是一种高效的、口服具有活力的PORCN 抑制剂(IC50:74 pM)。

细胞实验: Wnt-C59 (C59) is dissolved in DMSO (10 mM) and stored, and then diluted with appropriate medium before use[1]. Approximately, 1×104 cells are seeded in 24-well plates, and Wnt-C59 (5 μM, 10 μM, and 20 μM) is added the next day. Each group is tested in triplicate and control groups with addition of DMSO are also established. Cell confluence is determined by microscopy at 24, 48, 72, and 96 hours after seeding of cells. The IC50 of Wnt-C59 is determined by MTT assay, using 96-well dishes. Next day, various concentrations of Wnt-C59 are added, and cellular viabilities are measured by a spectrophotometer at both 24 and 48 hours. For sphere formation, approximately one hundred cells are seeded onto the Low Cell Bind Surface 24-well Nunc dish. Each group is done in triplicate and each well had 2 mL medium. Media are changed twice a week, and only half of the media is changed each time. Approximately, 1×103 cells are seeded for each well in the sphere inhibition assay. At 1 to 5 days after plating, all tested cells formed small spheres. Five days later, Wnt-C59 (1 μM, 5 μM, and 20 μM) is added into experimental groups. Abilities for cell growth and sphere images are compared and recorded at the end of the first, second, and third weeks after addition of Wnt-C59, or DMSO in control groups. The sphere growths are observed and recorded daily under microscopy, and the area of spheres is analyzed using Metamorph and recorded as average area (μm2)[1].

激酶实验: Aurora A radioactive Flashplate enzyme assay: Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.

体外活性: 在原位移植独立性MMTV-WNT1肿瘤的雌性裸鼠中,Wnt-C59（10 mg/kg）能够降低β-catenin靶向基因的表达,降低Wnt通路活性,抑制肿瘤细胞生长.14CREER/Rosa-SmoM2小鼠中,Wnt-C59（5 mg/kg）局部给药能够抑制细胞增殖.

体内活性: 在转染PORCN的无PORCN HT1080细胞中,Wnt-C59（100 nM ）抑制PORCN活性。在转染WNT3A-V5的HeLa细胞中,Wnt-C59（10 -100 nM）能够抑制PORCN酰基转移酶活性。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: Ethanol : 7.6 mg/mL (20 mM)
5% DMSO+95% Saline : 0.38 mg/mL (1 mM, suspension)
DMSO : 7.6 mg/mL (20 mM)


关键字: Wnt | WntC59 | Inhibitor | Porcupine | Wnt-C59 | Wnt-C-59 | inhibit | C 59 | C-59 | Wnt C59

相关产品: N-(3-Methoxybenzyl)-(9Z,12Z,15Z)-octadecatrienamide | Astragaloside I | JW74 | DK419 | Gliotoxin | EMT inhibitor-1 | Bisdemethoxycurcumin | IWR-1 | Tankyrase-IN-2 | Miclxin

相关库: Anti-Prostate Cancer Compound Library | Anti-Cancer Metabolism Compound Library | Neuronal Differentiation Compound Library | Bioactive Compounds Library Max | Osteogenesis Compound Library | Inhibitor Library | Anti-Obesity Compound Library | Anti-Colorectal Cancer Compound Library | Stem Cell Differentiation Compound Library | NO PAINS Compound Library